Island Pharmaceuticals (ASX:ILA) Cash And Cash Equivalents : A$3.99 Mil (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Island Pharmaceuticals Cash And Cash Equivalents?

Island Pharmaceuticals's quarterly cash and cash equivalents increased from Dec. 2023 (A$0.98 Mil) to Jun. 2024 (A$1.66 Mil) and increased from Jun. 2024 (A$1.66 Mil) to Dec. 2024 (A$3.99 Mil).

Island Pharmaceuticals's annual cash and cash equivalents declined from Jun. 2022 (A$4.79 Mil) to Jun. 2023 (A$2.00 Mil) and declined from Jun. 2023 (A$2.00 Mil) to Jun. 2024 (A$1.66 Mil).

Island Pharmaceuticals Cash And Cash Equivalents Historical Data

The historical data trend for Island Pharmaceuticals's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Island Pharmaceuticals Cash And Cash Equivalents Chart

Island Pharmaceuticals Annual Data

Trend

Jun21

Jun22

Jun23

Jun24

Cash And Cash Equivalents

6.46

4.79

2.00

1.66

Island Pharmaceuticals Semi-Annual Data
	Jun20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Cash And Cash Equivalents	Get a 7-Day Free Trial				3.43	2.00	0.98	1.66	3.99

Island Pharmaceuticals Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Island Pharmaceuticals (ASX:ILA) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Island Pharmaceuticals Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Island Pharmaceuticals's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Island Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Island Pharmaceuticals Ltd (ASX:ILA) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

c/- Bio101 Financial Advisory Pty Ltd, 697 Burke Road, Suite 201, Camberwell, Melbourne, VIC, AUS, 3124

Website

https://www.islandpharmaceuticals.com

Island Pharmaceuticals Ltd is a drug research and repurposing company focused on developing preventative or therapeutic drugs for viral infections. Its drug candidate ISLA-101 is a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and another mosquito (or vector) borne diseases. The company carries out its research and development activities principally in the geographic regions of Australia and the United States of America.

Island Pharmaceuticals Headlines

No Headlines